Form D · Biotechnology

Telo Therapeutics, Inc.

San Francisco, CA · CIK 0001868220

Offering snapshot reported Jun 21, 2022 · SEC filing

Reported sold
$4.71M
Offering amount: $10.2M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 9, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$2.36M$4.71MJun 22, 2021: $4,201,557.00Jun 22, 2021Jun 21, 2022: $4,711,552.00Jun 21, 2022

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$4,201,557 → $4,711,552

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 21, 2022Amendment$4,711,552$509,995vs Jun 22, 202112SEC filing
Jun 22, 2021Initial$4,201,557No comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-403696

Source: Form D, filed Jun 21, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Bell Director, Executive
Robert G. Blazej Director
Joseph Costello Director
Michael D. Taylor Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
953 Indiana Street
San Francisco, CA, 94107